SQ-3370 is under clinical development by Shasqi and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SQ-3370’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Shasqi is a clinical stage biotechnology company which works to enable patients to beat cancer without poisoning their bodies. The company’s CAPAC Platform is modular and can be applied to a broad range of drugs that are otherwise limited by toxicity. Shasqi is headquartered in San Francisco, California, the US.
For a complete picture of SQ-3370’s drug-specific PTSR and LoA scores, buy the report here.